Key Findings:  This literature search found emerging evidence suggests that endocannabinoidome (eCBome) plays a key role in immune responses, gut barrier integrity, and regulating inflammation; therefore, the eCBome presents potential therapeutic targets in inflammatory bowel disease.
Type of Study:  Meta-analysis
Study Result:  Positive
Research Location(s):  Australia
Year of Pub:  2025
Cannabinoids Studied:  Endocannabinoid (unspecified), Microbiome
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2, GPCR 55, TRPV1, PPAR - Alpha, GPCR
Citation:  Thapa D, Ghimire A, Warne LN, Carlessi R. Targeting the Endocannabinoidome: A Novel Approach to Managing Extraintestinal Complications in Inflammatory Bowel Disease. Pharmaceuticals (Basel). 2025 Mar 27;18(4):478. doi: 10.3390/ph18040478. PMID: 40283915; PMCID: PMC12030576.